Similar to the result in Figure 1C, combinedanti-PD-1/GITR mAb treatment significantly prolonged the survival of mice with 20% ofmice remaining tumor-free 90 days after tumor challenge, and cisplatin or paclitaxelpretreatment alone also modestly increased the survival of mice; strikingly, combinedtreatment of anti-PD-1/GITR mAb plus cisplatin or paclitaxel produced an impressingantitumor effect, resulting in the long-term survival of more than 80% mice (8 or 9mice out of 10 for anti-PD-1/GITR/cisplatin or anti-PD-1/GITR/paclitaxelrespectively) at the terminate of experiments (Figure 5B). Here, TNFRSF18 is linked to neoplasm.